{"publication_id":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","content_hash":"sha256:c655740df4fc9c4227832c867f5fd17a5db0fcbbf93443765f99ae2df38c759b","nodes":[{"id":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","type":"publication","title":"empagliflozin: one bounded, context-dependent signal across receipts"},{"id":"claim_1","type":"claim","text":"Across retrieved source-level receipts for empagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?"},{"id":"claim_2","type":"claim","text":"Finding: SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA."},{"id":"claim_3","type":"claim","text":"| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |"},{"id":"claim_4","type":"claim","text":"| outcome-specific | Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose... | directionally favorable | patients with type 2 diabetes mellitus | - | SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA |"},{"id":"claim_5","type":"claim","text":"| outcome-specific | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3... | directionally favorable | patients with T2DM and increased cardiovascular... | - | relative risk reductions in major adverse cardiac events (14%) |"},{"id":"claim_6","type":"claim","text":"This receipt-backed scoping note has one bounded signal: empagliflozin shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2016-2023). Evidence role grouping: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. The source facts cover 5 population/setting context(s) and 2 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim."},{"id":"claim_7","type":"claim","text":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable."},{"id":"claim_8","type":"claim","text":"directionally favorable: Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment — SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA."},{"id":"claim_9","type":"claim","text":"directionally favorable: Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials — relative risk reductions in major adverse cardiac events (14%)"},{"id":"claim_10","type":"claim","text":"Evidence role summary: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0."},{"id":"claim_11","type":"claim","text":"Specific moderators in this bundle are population/indication (CKD patients based on eGFR slopes; patients with T2DM and increased cardiovascular risk; patients with T2DM and/or HF; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and established cardiovascular disease), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable."},{"id":"claim_12","type":"claim","text":"Population/settings are separated as receipt context: CKD patients based on eGFR slopes, patients with T2DM and increased cardiovascular risk, patients with T2DM and/or HF, patients with type 2 diabetes mellitus, and patients with type 2 diabetes mellitus and established cardiovascular disease. The selected receipts group because each carries a fact-level extraction for empagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim."},{"id":"claim_13","type":"claim","text":"The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate."},{"id":"source_1","type":"source","study":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis","year":2021,"doi":"10.1093/eurjpc/zwab173","url":"https://doi.org/10.1093/eurjpc/zwab173","population":"patients with T2DM and/or HF","intervention_or_exposure":"empagliflozin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment","year":2020,"doi":"10.1161/jaha.119.015716","url":"https://doi.org/10.1161/jaha.119.015716","population":"patients with type 2 diabetes mellitus","intervention_or_exposure":"empagliflozin (SGLT-2i)","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","year":2016,"doi":"10.1161/circulationaha.116.021887","url":"https://doi.org/10.1161/circulationaha.116.021887","population":"patients with type 2 diabetes mellitus and established cardiovascular disease","intervention_or_exposure":"empagliflozin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","year":2016,"doi":"10.2174/1573399812666160613113556","url":"https://doi.org/10.2174/1573399812666160613113556","population":"patients with T2DM and increased cardiovascular risk","intervention_or_exposure":"empagliflozin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","year":2023,"doi":"10.1093/ckj/sfad082","url":"https://doi.org/10.1093/ckj/sfad082","population":"CKD patients based on eGFR slopes","intervention_or_exposure":"empagliflozin","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_1","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_2","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_3","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_4","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_5","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_6","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_7","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_8","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_9","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_10","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_11","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_12","type":"contains_claim"},{"from":"ba51abd9-ce97-48b3-b9e2-eb5a53bbd780","to":"claim_13","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}